C-stem technology, will enable Treefrog to develop an innovative cell therapy for the treatment of Parkinson’s disease. Taking advantage of the characteristics of its encapsulated 3D culture system, the company is the first in the world to offer a mature neural tissue transplant and a commercially exploitable bioprocess. Thanks to the support of the ERDF REACT EU, Treefrog must establish its manufacturing process, carry out pre-clinical tests and deploy its strategy. With a clinical start planned at the end of 2024 and a target of 20000 patients/year at the peak, Treefrog is positioned as one of the major initiatives on this indication globally and will contribute to the economic recovery in the territory.